Zylexis® is an inactivated (killed) Parapox Ovis Virus Immunomodulator and is indicated to aid in the reduction of upper respiratory disease associated with EHV 1 & 4 viral infection. This product is indicated for use in horses only.

DEMONSTRATED EFFICACY

- Aids in the reduction of upper respiratory disease associated with equine herpesvirus types 1 and 4.
- Zylexis treated horses showed significantly lower purulent nasal discharge ($p<0.01$) and clinical signs ($p<0.01$) than non-treated control horses\(^1\).
- Less days of mucopurulent nasal discharge were seen in Zylexis treated horses vs. the control group\(^1\).
- Decreased nasal discharge scores may indicate less bacterial infections following EHV 1 & 4 infections.

DEMONSTRATED SCIENCE

- A study of the Parapox Ovis Virus immunomodulator in horses has shown an improvement in immune response that is useful in reducing severity and duration of viral disease\(^2\).
- Parapox Ovis Virus activates immune cells, stimulates phagocytosis and induces expression of cytokines; the messenger proteins that stimulate production of interferon and immune cells in a number of species\(^3,4,5,6,7\).

DEMONSTRATED SAFETY

- None of the three-hundred and thirty-three Zylexis treated horses had visible or palpable reactions at the injection site or systemic reactions\(^8\).
- Zylexis is indicated for use in healthy horses over 4 months of age.

DOSAGE AND ADMINISTRATION

Dose:

- One 2 mL injection on days 0, 2 & 9 by intramuscular route.

When to Use:

- Treatment is recommended during disease episodes or prior to stress-inducing situations.
  Retreatment is recommended during subsequent disease episodes or prior to stress-inducing situations.
- EHV 1 & 4 infections can be easily triggered by common stressors to horses including trailering, competition, breeding and environmental changes.

Directions: Aseptically rehydrate the freeze-dried component with the sterile diluent provided, shake well and administer 2 mL intramuscularly. Repeat the 2 mL dose on days 2 and 9 following the initial dose. Retreatment is recommended during subsequent disease episodes or prior to stress-inducing situations.

Precautions: Store at 2°- 8° C. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this immunomodulator. Do not administer within 21 days before slaughter. In case of anaphylaxis, administer epinephrine or equivalent.
Frequently Asked Questions

Q. What is Zylexis?
A. Zylexis is an inactivated (killed) Parapox Ovis Virus Immunomodulator administered intramuscularly (IM).

Q: What are the indications for Zylexis?
A: Zylexis is indicated to aid in the reduction of upper respiratory disease associated with EHV 1 & 4 viral infections. This product is indicated for use in horses only.

Q: When do I use it?
A: Zylexis may be administered to horses prior to being subjected to possible stress and during disease episodes. EHV can be easily triggered by common stressors to horses including trailering, competition, breeding and environmental changes.

Q. What is the recommended dose?
A: Dosing consists of one 2 mL IM injection on days 0, 2 & 9. Retreatment is recommended during subsequent disease episodes or prior to stress inducing situations.

Q: Is Zylexis safe?
A: Zylexis has undergone testing in a field safety trial in the US in 333 horses of various breeds ranging in age from 4 months to 20 years. No adverse events were reported.

Q: How often should I use Zylexis?
A: Zylexis may be administered during subsequent disease episodes or before potentially stress-inducing events such as trailering, competition, breeding, racing or environmental changes.

Q: Can I use Zylexis in foals?
A: Yes. Zylexis is indicated for healthy horses over 4 months of age.

1 Data on File, Pfizer Study No. Equine 1-98
8 Data on File, Pfizer Study No. Nov. 20, 2000